肠道微生态对肿瘤免疫治疗的影响

Effects of intestinal microbiota on cancer immunotherapy

近年来,研究表明肠道微生态对肿瘤免疫治疗有重要的影响,肠道微生态与各类免疫检查点抑制剂如抗细胞毒性T淋巴细胞相关抗原4抗体、抗程序性细胞死亡蛋白1抗体以及抗程序性细胞死亡蛋白配体1抗体的疗效密切相关。本文回顾分析了相关基础及临床研究的最新进展,发现诸如Akkermansia muciniphila、双歧杆菌等重要有益菌可提升肿瘤免疫治疗的效果并作为生物标志物。因此,推测多样化的肠道微生态有利于维持机体内环境稳定,肠道微生态的合理调控可提高肿瘤免疫治疗效果,并减轻不良反应。

Recent studies indicate that intestinal microbiota plays an important role in cancer immunotherapy.Intestinal microbiota is closely related to the treatment effect of immune checkpoint inhibitors targeting cytotoxic T lymphocyte associated antigen 4,programmed cell death protein 1 and programmed cell death protein 1 ligand.Our study analyzes recent progress of related basic and clinical studies and finds that several bacteria such as Akkermansia muciniphila and Bifidobacterium can improve cancer immunotherapy efficacy and may act as a biomarker.Therefore,we conclude that diversified intestinal microbiota can maintain the stability of the internal environment,and equitable regulation of intestinal microbiota can improve the efficacy of cancer immunotherapy and reduce adverse reactions.